Antiadrenergic therapy of chronic heart failure: Surprises and new opportunities

Circulation

Volumn 107, Issue 8, 2003, Pages 1100-1102

  Bristow, Michael ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Heart failure; Nervous system, sympathetic; Receptors, adrenergic, alpha; Receptors, adrenergic, beta

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CARVEDILOL; CELIPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAZOLINE RECEPTOR; METOPROLOL; MOXONIDINE; NORADRENALIN; PHOSPHODIESTERASE INHIBITOR; XAMOTEROL;

ADRENERGIC ACTIVITY; ADRENERGIC SYSTEM; ADVERSE DRUG REACTION; CLINICAL TRIAL; CORONARY SINUS; DISEASE COURSE; DOWN REGULATION; DRUG FATALITY; DRUG RESPONSE; HEART FAILURE; HUMAN; INTRINSIC SYMPATHOMIMETIC ACTIVITY; LONG TERM CARE; MEDICAL RESEARCH; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION;

ADRENERGIC BETA-ANTAGONISTS; CHRONIC DISEASE; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC; SYMPATHOLYTICS;

EID: 0037418250     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000054530.87613.36     Document Type: Review

References (25)

1. Whitehead AN. Whitehead's American Essays in Social Philosophy. Westport, Conn: Greenwood Press; 1975.
2. Braunwald EB, Bristow MR. Congestive heart failure: fifty years of progress. Circulation. 2000;102:14-23.
3. Gaffney TE, Braunwald EB. Importance of the adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. Am J Med. 1963;34:320-324.
4. Bristow MR. β-adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101:558-569.
5. Coats AJ. Heart failure 99: the MOXCON story Int J Cardiol. 1999;71:109-111.
6. Swedberg K, Bristow MR, Cohn JN, et al, for the MOXSE Investigators. The effects of moxonidineSR, an imidazoline agonist, on plasma norepinephrine in patients with congestive heart failure. Circulation. 2002;105:1797-1803.
7. Bristow M, Krause-Steinrauf H, Abraham W, et al. Sympatholytic effect of bucindolol adversely affected survival, and was disproportionately observed in the class IV subgroup of BEST. Circulation. 2001;104:II-755.
8. BEST Trial Investigators. A trial of the β-adrenergic blocker bucindolol in patients with advanced heart failure. N Engl J Med. 2001;344:1659-1667.
9. Domanski MJ, Krause-Steinrauf H, Deedwania PC, et al. A comparative analysis of the results of three trials of β-blocker therapy for heart failure: BEST, CIBIS-II, and MERIT-HF. J Cardiac Failure. 2001;7(Suppl 3):56.
10. Bristow MR, Shakar SF, Linseman JV, et al. Inotropes and β-blockers: is there a need for new guidelines? J Cardiac Failure. 2001;7(2 Suppl 1):8-12.
11. Lowes BD, Gilbert EM, Lindenfeld JA, et al. Differential effects of β-blocking agents on adrenergic activity. Circulation. 2000;102:II-628.
12. The Xamoterol in Severe Heart Failure Study Group. Xamatoterol in severe heart failure. Lancet. 1990;336:1-6.
13. Witchitz S, Cohen-Solal A, Dartois N, et al. Treatment of heart failure with celiprolol, a cardioselective β-blocker with β-2 agonist vasodilatory properties: the CELICARD Group. Am J Cardiol. 2000;85:1467-1471.
14. Willette RN, Aiyar N, Yue TL, et al. In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats. J Pharmacol Exp Ther. 1999;289:48-53.
15. Andreka P, Aiyar N, Olson LC, et al. Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation. 2002;105:2429-2434.
16. Maack C, Cremers B, Flesch M, et al. Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. Br J Pharmacol. 2000;130:1131-1139.
17. Sederberg J, Wichman SE, Lindenfeld J, et al. Bucindolol has no sympathomimetic activity in nonfailing ventricular preparations. J Am Coll Cardiol. 2000;35:207A.
18. Brixius K, Bundkirchen A, Bolck B, et al. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol. 2001:133:1330-1338.
19. Bristow MR, Roden RL, Lowes BD, et al. The role of third generation β-blocking agents in chronic heart failure. Clinical Cardiology. 1998; 21(Suppl I):I-3-I-13.
20. Engelhardt S, Grimmer Y, Fan GH, et al. Constitutive activity of the human β(1)-adrenergic receptor in β(1)-receptor transgenic mice. Mol Pharmacol. 2001;60:712-717.
21. Metra M, Giubbini R, Nodari S, et al. Differential effects of β-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation. 2000;102:546-551.
22. Lowes BD, Gilbert EM, Abraham WT, et al. Myocardial gene expression in dilated cardiomyopathy treated with β-blocking agents. N Engl J Med. 2002;346:1357-1365.
23. Bristow MR. What type of β-blocker should be used to treat chronic heart failure? Circulation. 2000;102:484-486.
24. 2c-adrenergic receptors and the risk of congestive heart failure. N Engl J Med. 2002;347:1135-1142.
25. McNamara DM, Holubkov R, Janosko K, et al. Pharmacogenetic interactions between β-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation. 2001;103:1644-1648.